Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

This trial is testing whether adding the targeted antibody drug nimotuzumab to a standard chemotherapy regimen (gemcitabine plus albumin-bound paclitaxel, called AG) improves outcomes in patients with pancreatic cancer that has spread to the liver. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) with liver metastases, confirmed by biopsy or cytology - Your cancer is not suitable for surgery or radical radiation - You have at least one measurable lesion on imaging - Your general health score (KPS) is 60 or above - Your expected survival is more than 3 months - Your blood counts and organ function (liver, kidneys) are within acceptable ranges **You may NOT be eligible if...** - You have already received palliative chemotherapy or targeted therapy for pancreatic cancer - You have cancer that has spread to the brain - You have had major surgery within 4 weeks - You are currently participating in another clinical trial - You are pregnant or not using contraception if childbearing is possible Talk to your doctor to see if this trial is right for you.